Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study

HAYWARD, Calif., Dec. 15, 2022 /PRNewswire/ -- Avirmax CMC Inc. (ACI), a global leader in recombinant adeno associated vector (rAAV) bioprocess development and manufacturing, using a recombinant baculovirus Sf9 cell (rBV-Sf9-AAV) system, has manufactured, tested and released its first...

Click to view original post